Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma
- 30 April 2006
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (3) , 297-302
- https://doi.org/10.1016/j.ejso.2005.11.020
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Gemcitabine-based therapy in pancreas cancerCancer, 2002
- Gemcitabine: Progress in the Treatment of Pancreatic CancerOncology, 2000
- The role of gemcitabine alone and in combination in the treatment of pancreatic cancerAnti-Cancer Drugs, 2000
- A phase I–II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)Annals of Oncology, 1999
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinomaCancer, 1996
- Activity of gemcitabine in patients with advanced pancreatic carcinoma: A reviewCancer, 1996
- Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnnals of Oncology, 1996
- Randomized clinical trials in oncology: Principles and obstaclesCancer, 1994
- A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinomaCancer, 1991